ChemGenex on a roll
Tuesday, 01 July, 2008
ChemGenex [ASX: CXS] has submitted the non-clinical section of its New Drug Application [NDA] to the US FDA for omacetaxine, the company's chronic myeloid leukaemia treatment.
The non-clinical section is the first of three in the company's rolling submission: the next steps are the chemistry and manufacturing controls segment and the clinical section.
ChemGenex expects that both remaining submissions will be complete by mid-2009.
The FDA has already granted fast-track designation to the drug, omacetaxine mepesuccinate, for treatment of patients who have failed prior treatment with Novartis' imatinib mesylate, or Glivec.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
